The Comparison of the Outcomes of antibiotic Drugs and Appendectomy, or CODA, Trial is the largest study to date comparing appendectomy and antibiotics for appendicitis, with 1,552 participants enrolled (roughly three times larger than the previous largest trial) from 25 sites in 14 states. Funded by the Patient-Centered Outcome Research Institute and designed in partnership with patient stakeholders, the CODA Trial aims to answer the question, “Based on my unique characteristics, preferences, and outcomes of interest, are antibiotics as good as appendectomy?”
The CODA trial focuses on clinical outcomes—broadly agreed, measurable changes in health—as well as the patient-reported outcomes (PROs) that matter most to patients. Results of this study will support an evidence-based approach to appendicitis care and help nearly 300,000 Americans each year make an important healthcare decision about this common condition.
The CODA Trial reached its enrollment goals on February 5, 2020, with 1,552 study participants enrolled in the randomized cohort, 518 in the observational cohort, and 2,112 in the EMR cohort. Study participants are contributing follow-up data for up to 5 years after their initial treatment.
CODA Trial primary outcome results were published on October 5, 2020, in the New England Journal of Medicine. The CODA Trial team will share additional results of the study over the next 2 years.
The CODA Trial is funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (1409-24099).